[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nk-cell-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nk-cell-lymphoma":85},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,71,130,157],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100515709","phase-1-universal-4scar7u-targeting-cd7-positive-malignancies-100515709",false,"NCT05995028","Universal 4SCAR7U Targeting CD7-positive Malignancies","Safety and Efficacy of Universal 4SCAR7U T Cell Therapy Targeting CD7-positive Hematological Malignancies","Inclusion Criteria:\n\n1. Age older than 6 months.\n2. Confirmed expression of CD7 and additional surface antigens in the cancer cells by immuno-histochemical staining or flow cytometry.\n3. Karnofsky performance status (KPS) score is higher than 80 and life expectancy \\> 3 months.\n4. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%, creatinine ≤ 2.5 × upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal, total bilirubin ≤ 2.0mg\u002FdL.\n5. Hgb≥80g\u002FL.\n6. No cell separation contraindications.\n7. Abilities to understand and the willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Sever illness or medical condition, which would not permit the patient to be managed according to the protocol, including active uncontrolled infection.\n2. Active bacterial, fungal or viral infection not controlled by adequate treatment.\n3. Known HIV or hepatitis C virus (HCV) infection.\n4. Pregnant or nursing women may not participate.\n5. Use of glucocorticoid for systemic therapy within one week prior to entering the trial.\n6. Previous treatment with any gene therapy products.\n7. Patients, in the opinion of investigators, may not be able to comply with the study.","ALL","6 Months","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells. The study also aims to learn more about the function of CD7 targeting CAR T cells and their persistence in patients of hematological malignancies.",[27,28,29,30],"T-cell Acute Lymphoblastic Leukemia","T-cell Acute Lymphoblastic Lymphoma","Acute Myeloid Leukemia","NK Cell Lymphoma",[32,33,34,35,36,37],"T-ALL","TCL","AML","NK lymphoma","Universal CAR T","CD7","RECRUITING","2026-06-18",{"date":41,"type":42},"2026-06-23","ACTUAL",{"date":44,"type":42},"2023-10-31",{"date":46,"type":21},"2026-12-31",{"name":48,"class":49},"Shenzhen Geno-Immune Medical Institute","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":50},"100365058","phase-1-multi-car-t-cell-therapy-targeting-cd7-positive-malignancies-100365058","NCT04033302","Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies","A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies","Inclusion Criteria:\n\n1. Age older than 6 months.\n2. Confirmed expression of CD7 or additional surface antigens in the cancer cells by immuno-histochemical staining or flow cytometry.\n3. Karnofsky performance status (KPS) score is higher than 80 and life expectancy \\> 3 months.\n4. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%, creatinine ≤ 2.5 × upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal, total bilirubin ≤ 2.0mg\u002FdL.\n5. Hgb≥80g\u002FL.\n6. No cell separation contraindications.\n7. Abilities to understand and the willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Sever illness or medical condition, which would not permit the patient to be managed according to the protocol, including active uncontrolled infection.\n2. Active bacterial, fungal or viral infection not controlled by adequate treatment.\n3. Known HIV or hepatitis C virus (HCV) infection.\n4. Pregnant or nursing women may not participate.\n5. Use of glucocorticoid for systemic therapy within one week prior to entering the trial.\n6. Previous treatment with any gene therapy products.\n7. Patients, in the opinion of investigators, may not be able to comply with the study.",{"count":20,"type":21},[24,60],"PHASE2","The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cell therapy against CD7-positive hematological malignancies using CD7 specific CAR T cells. The study also aims to learn more about the function of CD7 CAR T cells and their persistence in patients of hematological malignancies.",[27,28,29,30],[32,33,34,35,64,37],"CAR T",{"date":41,"type":42},{"date":67,"type":42},"2026-06-01",{"date":69,"type":21},"2030-12-31",{"name":48,"class":49},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":115,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100514411","a-registry-for-people-with-t-cell-lymphoma-100514411","NCT05978141","A Registry for People With T-cell Lymphoma","The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens","Inclusion Criteria:\n\n* Written informed consent\n* Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.\n* Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):\n\n  * T-cell prolymphocytic leukemia\n  * T-cell large granular lymphocytic leukemia\n  * Chronic lymphoproliferative disorder of NK cells\n  * Aggressive NK-cell leukemia\n  * Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood\n  * Chronic active EBV infection of T- and NK-cell type, systemic form\n  * Hydroa vacciniforme-like lymphoproliferative disorder\n  * Adult T-cell leukemia\u002Flymphoma\n  * Extranodal NK\u002FT-cell lymphoma, nasal type\n  * Enteropathy-associated T-cell lymphoma\n  * Monomorphic epitheliotropic intestinal T-cell lymphoma\n  * Intestinal T-cell lymphoma, not otherwise specified (NOS)\n  * Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract\n  * Hepatosplenic T-cell lymphoma\n  * Subcutaneous panniculitis-like T-cell lymphoma\n  * Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)\n  * Sézary syndrome\n  * Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)\n  * Primary cutaneous Gamma-Delta T-cell lymphoma\n  * Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma\n  * Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)\n  * Peripheral T-cell lymphoma, not otherwise specified\n  * Angioimmunoblastic T-cell lymphoma\n  * Follicular T-cell lymphoma\n  * Nodal peripheral T-cell lymphoma with TFH phenotype\n  * Anaplastic large cell lymphoma, ALK-positive\n  * Anaplastic large cell lymphoma, ALK-negative\n  * Breast-implant associated anaplastic large cell lymphoma.\n* NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and\u002For primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.\n\nExclusion Criteria:\n\n* Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and\u002For primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.\n* Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.",{"count":79,"type":21},1000,"10 Years","OBSERVATIONAL","The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.",[84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114],"T-cell Lymphoma","NK-Cell Lymphoma","T-cell Prolymphocytic Leukemia","T-cell Large Granular Lymphocytic Leukemia","Chronic Lymphoproliferative Disorder of NK Cells","Aggressive NK-cell Leukemia","Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)","Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood","Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form","Hydroa Vacciniforme-Like Lymphoproliferative Disorder","Adult T-cell Leukemia\u002FLymphoma","Extranodal NK\u002FT-cell Lymphoma, Nasal Type","Enteropathy-associated T-cell Lymphoma","Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma","Intestinal T-Cell Lymphoma, Not Otherwise Specified","Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","Hepatosplenic T-cell Lymphoma","Subcutaneous Panniculitis-Like T-Cell Lymphoma","Mycosis Fungoides","Sezary Syndrome","Primary Cutaneous Anaplastic Large Cell Lymphoma","Primary Cutaneous T-cell Lymphoma","Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma","Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified","Angioimmunoblastic T-cell Lymphoma","Follicular T-Cell Lymphoma","Nodal Peripheral T-Cell Lymphoma With TFH Phenotype","Anaplastic Large Cell Lymphoma, ALK-Positive","Anaplastic Large Cell Lymphoma, ALK-negative","Breast Implant-Associated Anaplastic Large Cell Lymphoma",[116,117,118,119,120],"23-190","T-cell lymphoma","Memorial Sloan Kettering Cancer Center","T-cell Lymphoma Master Repository","TCLMR","2026-05-18",{"date":123,"type":42},"2026-05-20",{"date":125,"type":42},"2023-07-27",{"date":127,"type":21},"2030-07-27",{"name":118,"class":49},26,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100340943","early-phase-1-chemoimmunotherapy-and-allogeneic-stem-cell-transplant-for-nk-t-cell-leukemialymphoma-100340943","NCT03719105","Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia\u002FLymphoma","Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma\u002FLeukemia in Children, Adolescents and Young Adults; A NK\u002FT-Cell Lymphoma\u002FLeukemia Consortium Study","Inclusion Criteria:\n\n* Patients must weigh at least 10 kilograms at the time of the study enrollment.\n* Diagnosis\n\nNewly diagnosed patients with histologically proven mature T- and NK- cell neoplasms:\n\nCOHORT 1\n\n* Aggressive NK cell leukemia (ICD-O code 9948\u002F3)\n* Extranodal NK\u002FT-cell lymphoma, nasal type (ICD-O code 9719\u002F3) COHORT 2\n* Enteropathy-associated T-cell lymphoma (ICD-O code 9717\u002F3)\n* Hepatosplenic T-cell lymphoma (ICD-O code 9716\u002F3)\n* Peripheral T-cell lymphoma, non-otherwise specified (ICD-O code 9702\u002F3)\n* Angioimmunoblastic T-cell lymphoma (ICD-O code 9705\u002F3)\n* Other mature T- and NK-cell neoplasm histologies will considered after case-by-case discussion with Study Chairs and executive Vice-Chair Patients with lymphoma must have stage III or IV disease (See Appendix III for Staging).\n\n  * Organ Function Requirements\n\nAdequate liver function defined as:\n\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age.\n* ALT (SGPT) \\\u003C 3 x ULN for age.\n\nAdequate cardiac function defined as:\n\n* Shortening fraction of ≥ 27% by echocardiogram, or\n* Ejection fraction of ≥ 50% by radionuclide angiogram.\n\nAdequate pulmonary function defined as:\n\n• Patients with a history of pulmonary dysfunction must have no evidence of dyspnea at rest, no exercise intolerance due to pulmonary insufficiency, and a pulse oximetry \\> 92% while breathing room air unless current dysfunction is due to the lymphoma, in which case the patient is eligible.\n\nExclusion Criteria:\n\n* Alk+ or Alk- Anaplastic Large Cell Lymphoma (ALCL)\n* Patients with active CNS disease.\n* Patients with stage I or stage II disease (See Appendix III for Staging).\n* Patients who have received any prior cytotoxic chemotherapy for the current diagnosis of NHL.\n* Previous steroid treatment and\u002For radiation treatment are not allowed unless they are used for emergency management. Patients who have received emergency irradiation and\u002For steroid therapy will be eligible only if started on protocol therapy not more than one week from the start of radiotherapy or steroids.\n* Female patients who are pregnant. Pregnancy tests must be obtained in girls who are post menarchal.\n* Lactating females, unless they have agreed not to breastfeed their infants.\n* Patients with Down syndrome.\n* Patients taking CYP3A4 substrates with narrow therapeutic indices. Patients (COHORT 2 ONLY) chronically receiving medications known to be metabolized by CYP3A4 and with narrow therapeutic indices (See Appendix V). The topical use of these medications (if applicable) is allowed.\n* Patients taking CYP3A4 inhibitors. Patients (COHORT 2 ONLY) chronically receiving drugs that are known potent CYP3A4 inhibitors within 7 days prior to study enrollment (See Appendix V). The topical use of these medications (if applicable) is allowed.\n* Patients taking CYP3A4 inducers. Patients (COHORT 2 ONLY) chronically receiving drugs that are known potent CYP3A4 inducers within 12 days prior to study enrollment (See Appendix V).","1 Year","31 Years",{"count":140,"type":21},40,[142],"EARLY_PHASE1","Patients are in 2 cohorts:\n\nCohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide, doxorubicin, and prednisone in children, adolescent, and young adults with advanced peripheral T-cell lymphoma (non-anaplastic large cell lymphoma or non-NK lymphoma\u002Fleukemia) .\n\nBoth groups proceed to allogeneic stem cell transplant with disease response.",[85,145,146],"NK-Cell Leukemia","Peripheral T Cell Lymphoma","2025-08-07",{"date":149,"type":42},"2025-08-08",{"date":151,"type":42},"2019-03-01",{"date":153,"type":21},"2028-12-31",{"name":155,"class":49},"New York Medical College",6,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100469133","screening-for-oculocerebral-lymphoma-with-the-phenotype-of-nk-cells-in-patients-with-uveitis-100469133","NCT05388838","Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis","Screening for Oculocerebral Lymphoma by Identifying the Phenotype Carried by Circulating NK Cells in Patients with Uveitis","DeLPHy","Inclusion Criteria:\n\nGENERAL CRITERIA\n\n* Male or female over 18 years of age,\n* Free, informed, written consent signed by the patient and the investigator (at the latest on the day of inclusion) and before any examination required by the research,\n* Patient affiliated to the social security system or beneficiary of such a system,\n* Maximum volume of sampling (care + research) per 30-day period to be adapted according to the patient's weight (Order of April 12, 2018 establishing the list of research mentioned in 2° of Article L. 1121-1).\n\nSPECIFIC CRITERIA\n\n\\- Patient affected in one or both eyes: of uveitis with another diagnosis than ocular lymphoma and without cerebral lymphoma (Group 1), or primary ocular lymphoma without brain involvement and never treated (Group 2), or primary ocular lymphoma without brain involvement, treated and considered in remission (IL10 HA level \\\u003C 10) (Group 3), or primary ocular lymphoma without brain involvement, and considered in relapse (IL10 HA level \\> 30) (Group 4), or cerebral lymphoma with or without ocular involvement and without uveitis (Group 5), or cataract (pre- and post-op), glaucoma, retinal detachment or epiretinal retinal detachment or epiretinal membrane, but no brain damage or uveitis (group 6).\n\nExclusion Criteria:\n\n* -GENERAL CRITERIA\n* Patient participating in an ongoing clinical trial at the time of the inclusion visit,\n* Pregnant women, women in labor or nursing mothers,\n* Persons deprived of liberty by a judicial or administrative decision,\n* Persons under psychiatric care,\n* Persons admitted to a health or social institution for purposes other than research,\n* Persons of full age who are subject to a legal protection measure (guardianship, curatorship).\n\nSPECIFIC CRITERIA\n\n* Patient for whom the diagnosis of ocular or cerebral lymphoma is uncertain,\n* Patient with another systemic cancer that is evolving or in remission \\\u003C 2 years.","18 Years",{"count":167,"type":21},60,[169],"NA","Uveitis is an inflammation of the uvea, an ocular tunic comprising the iris, ciliary body and choroid. This inflammation can also involve other tissues such as the retina, the optic nerve and the aqueous humor. These diseases can result in significant vision loss and account for 10% of all blindness in developed countries, and up to 25% in developing countries. The main difficulty in this pathology is to make the etiological diagnosis, which then allows a specific treatment of the disease. The main etiologie are inflammatory or infectious (sarcoidosis, tuberculosis) but other cancerous etiologies are possible and are of more complicated diagnosis.\n\nVitreoretinal lymphoma is a subtype of central nervous system lymphoma, which is generally associated with a poor prognosis. It is a diffuse non-Hodgkin's lymphoma, with large B cells. It can be primary ocular (Primary Intra-Ocular Lymphoma - LIOP), without brain involvement, but can also be secondary to central nervous system involvement, which explains the poor prognosis of the disease. Approximately 50-90% of LIOP develop brain involvement within 1-2 years of diagnosis, which encourages early diagnosis to avoid brain involvement as much as possible.\n\nThe main obstacle to rapid diagnosis is the difficulty of identifying LIOP. Indeed, the clinical symptoms of this rare disease are often identical to classical uveitis, and the diagnostic means to detect it are invasive and require a trained ophthalmologist and hematologist team. LIOP diagnostic tests are often delay in the management of uveitis and lead to diagnostic erraticity that can last between 4 to 40 months.\n\nThe INSERM U1183 unit is developing a diagnostic technology for lymphomas based on the analysis of blood NK cells and their phenotypes including those acquired by trogocytosis (WO\u002F2016\u002F005548).\n\nA rapid, simple, minimally invasive LIOP test using this technology could therefore be propose to all patients presenting with uveitis and whose clinical criteria could match those of LIOP.\n\nThe research hypothesis is : Could the diagnostic wandering of patients with primary intraocular lymphoma be reduced by a rapid blood test for NK cell phenotype of patients with uveitis? Following a simple blood test, a rapid LIOP test, using this diagnostic technology, could therefore be proposed to all patients with uveitis and clinical criteria (age, intermediate and posterior location of the uveitis) corresponding to those of LIOP.\n\nThe primary objective of this study is to compare the phenotype of circulating NK cells of patient with untreated intraocular lymphoma versus the phenotype of patient with non-cancerous uveitis.",[172,173,85],"Uveitis","Lymphoma","2025-02-28",{"date":176,"type":42},"2025-03-03",{"date":178,"type":42},"2022-06-01",{"date":180,"type":21},"2025-12-01",{"name":182,"class":49},"Hospices Civils de Lyon",2]